What Makes Mysimba® Different?
There is no generic or generic equivalent to Mysimba® on the market today. Mysimba® is a unique, patented, combination of two drugs — naltrexone and bupropion — within a single prolonged-release tablet clinically proven to help your patients lose weight and keep it off when combined with diet and exercise. Mysimba® is the ONLY prescription medication that contains naltrexone in a prolonged release, oral formulation.
The individual medicines of naltrexone and bupropion are not the same dose or formulation used in Mysimba® and are not approved for weight loss when used on their own.
Prescribing Authentic Mysimba®
The following images show an authentic Mysimba® tablet (left) and Mysimba® outer carton (right):
If your patient’s medication or outer carton does not look like this then they do not have a Mysimba® prescription. There is no generic or generic equivalent to Mysimba® on the market today. If you think you there was a mistake made with your patient’s medication, please double check the prescription and get in touch with the dispensing pharmacy.
Your Patients Get:
PATENTED DESIGN
Each Mysimba® tablet has patented 3-layers with a special prolonged-release coating.
Please refer to the Mysimba® Summary of Product Characteristics (SmPC)
▼ Black Triangle
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Please refer to the Mysimba® Summary of Product Characteristics (SmPC)
▼ Black Triangle
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Please refer to the Mysimba® Summary of Product Characteristics (SmPC)
▼ Black Triangle
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
